Actinium (NYSE: ATNM) Highlights Oral Presentation at #EHA2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial. Read the press release here: https://bit.ly/3VqCTQL #BMT
Actinium Pharmaceuticals, Inc.’s Post
More Relevant Posts
-
Applying RCT and Real-World Drug-Eluting Data to Clinical Practice. This live-case symposium features case operator John Phillips, MD, joined by panelists Mac Ansari, MD, Yolanda Bryce, MD and Patrick Harty, MD. Throughout the case, the value of IVUS and drug elution are demonstrated and discussed along with data updates on Ranger, Eluvia, and the ELEGANCE registry. https://okt.to/Tlnpdc
To view or add a comment, sign in
-
Check out the upcoming webinar on 'hot takes' in precision medicine moderated by Katie Maloney!
Live from London! We're hosting a webinar with TTP plc next month! Join us for a dynamic panel discussion featuring key opinion leaders taking the hot seat to share their contrarian thoughts on the most pressing issues in the precision medicine space. This webinar promises engaging insights, thought-provoking discussions, and the opportunity to witness minds being changed in real-time. In the Hot Seat: Challenging Conventions in Precision Medicine Thursday, March 7th, 2024 3:00 pm - 4:00 pm GMT / 10:00 am - 11:00 am EST Registration is limited. Save your spot today: https://lnkd.in/g-q7bZkx #PrecisionMedicine #AGBT24 #Webinar
To view or add a comment, sign in
-
Precision Medicine will help patients get more appropriate drugs? Duh! NGS is the future of genomics? Boring! Reimbursement will take time to catch up with innovation? Obviously! Enough with the popular opinions, we want contrarian perspectives! Join our webinar on March 7th to hear some of the industries leading KOLs share their hot takes in precision medicine and have a chance to vote on if your mind has been changed. Find the registration link below!
Live from London! We're hosting a webinar with TTP plc next month! Join us for a dynamic panel discussion featuring key opinion leaders taking the hot seat to share their contrarian thoughts on the most pressing issues in the precision medicine space. This webinar promises engaging insights, thought-provoking discussions, and the opportunity to witness minds being changed in real-time. In the Hot Seat: Challenging Conventions in Precision Medicine Thursday, March 7th, 2024 3:00 pm - 4:00 pm GMT / 10:00 am - 11:00 am EST Registration is limited. Save your spot today: https://lnkd.in/g-q7bZkx #PrecisionMedicine #AGBT24 #Webinar
In the Hot Seat: Challenging Conventions in Precision Medicine
info.ttp.com
To view or add a comment, sign in
-
“When these two tests (PET/CT and ctDNA) are discordant, ctDNA may be the more reliable of the two.” In this video, Brian Sworder discusses recently presented data from a prospective real-world study that compared response assessment by ctDNA vs. PET/CT Key findings: - ctDNA more accurately predicted PFS and OS at a higher hazard ratio than PET/CT - ctDNA had both better positive and negative predictive value for EOT response than PET/CT - Among discordant cases of patients who were PET positive but MRD negative, none have progressed to date - Among discordant cases of patients who were PET negative but MRD positive, a number of patients progressed https://lnkd.in/dTpQ8adG #ctdna #mrd #ash23 #lymphoma #precisionmedicine
Prospective real-world study on the utility of PhasED-Seq MRD - Dr. Brian Sworder, ASH 2023
https://www.youtube.com/
To view or add a comment, sign in
-
🇩🇰📢 First@ #CIRSE2023 First report of #SAVE_AVF RCT evaluating the safety & efficacy of #SELUTIONSLR in treatment of stenotic AV fistula, presented by Prof Dr. Konstantinos Katsanos, MSc MD PhD EBIR 👉🏼SAVE is the first prospective randomized controlled trial of a Sirolimus coated balloon in AVF patients with angiographic follow up. Additionally, fistula volume flow rates, another key index of fistula function, was measured in this study. 👉Uniform distribution of patient and lesion characteristics were observed which indicates a well-balanced subject selection and enrollment. 👉The findings indicate improvements in minimum lumen diameter (MLD) and flow rate after procedure, all of which are statistically significant in both arms. 👉🏼SELUTION SLR demonstrated a safe procedural profile, with no serious adverse events reported and an excellent device success rate (100%) 👉🏼The analysis of the 6 months follow up of the full cohort is currently ongoing. Jeffrey B. Jump Andrew Murtagh Amanda Williams Karin Bortolin Tamara Solaja Susanne Meis
To view or add a comment, sign in
-
Mölnlycke® Z-Flo® Fluidized Positioners can be moulded to shape and positioned under a patient’s head to redistribute contact pressures and alleviate surface and subdermal tissue deformations at the occipital region. Results showed a statistically significant reduction in occipital PIs by 87.7%* . Find out more here: https://bit.ly/2VWAimO *Barakat-Johnson M et al. Evaluation of a fluidised positioner to reduce occipital pressure injuries in intensive care patients: A pilot study. Int Wound J. 2018;1–9
To view or add a comment, sign in
-
🚨 CMG Update 🚨 The following Clinical Management Guidelines (CMG) have been reviewed and updated: ☑️ Keratitis (CL associated, infiltrative) ☑️ Marginal keratitis ☑️ Photokeratitis ☑️ Cellulitis (pre-septal and orbital) ☑️ Contact lens associated papillary conjunctivitis (CLAPC) ☑️ Endophthalmitis College members can view a summary of the updates made to the CMGs on our website ➡️ https://coptom.uk/CMGs
To view or add a comment, sign in
-
Our recently published randomised self-controlled trial (RCT) compared the rate of healing of chronic VLUs with and without the geko™ device, with each patient acting as their own control. The study measured the rate of healing using wound margin advance (WMA) and percentage area reduction (PAR). The results show that the addition of the geko™ device to standard of care (SoC) more than doubled the rate of healing of VLUs compared with SoC alone. Click here to learn more: https://lnkd.in/gz-a2BiX
To view or add a comment, sign in
-
Our recently published randomised self-controlled trial (RCT) compared the rate of healing of chronic VLUs with and without the geko™ device, with each patient acting as their own control. The study measured the rate of healing using wound margin advance (WMA) and percentage area reduction (PAR). The results show that the addition of the geko™ device to standard of care (SoC) more than doubled the rate of healing of VLUs compared with SoC alone. Click here to learn more: https://lnkd.in/gz-a2BiX
To view or add a comment, sign in
12,797 followers